Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration

Ferric carboxymaltose (FCM) is a novel iron formulation increasingly prescribed due to its effectiveness and fast infusion time. FCM administration can cause an asymptomatic hypophosphataemia secondary to fibroblast growth factor 23 (FGF23) dysregulation. In patients with chronic iron needs, however...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Case Rep
Main Authors: Klein, Klara, Asaad, Shonda, Econs, Michael, Rubin, Janet E
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5775795/
https://ncbi.nlm.nih.gov/pubmed/29298794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222851
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados